Next-generation incretin drugs
Triple agonists and amylin combinations such as retatrutide and CagriSema.
Key point
CagriSema led to a greater proportion of adults with obesity achieving BMI and waist-to-height ratio targets than semaglutide, cagrilintide, or placebo.
From: Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1 (Diabetes Obes Metab, 2026 Oct) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 7, 19, 26, 18, 28.
All papers from the last 12 months
199 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?Lancet2026 Dec 20PMID 41207308Review
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medicationsJ Diabetes Metab Disord2026 DecPMID 42871568Review
- Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 DiabetesDiabetes Obes Metab2026 NovPMID 42608321RCT
- Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feedingPhysiol Behav2026 Nov 1PMID 42603595
- Medical treatments for obesity: what does the future have in store?J Clin Endocrinol Metab2026 Oct 16PMID 42444567Review
- Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetesJ Clin Endocrinol Metab2026 Oct 16PMID 42135195RCT
- Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profileJ Mol Histol2026 Oct 15PMID 42878930
- Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat TransferAesthet Surg J2026 Oct 15PMID 42219269
- GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?Acta Diabetol2026 Oct 14PMID 42873315Review
- Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?Diabetes Obes Metab2026 Oct 12PMID 42864267
More endocrinology trends
All specialties →Tirzepatide
A dual GIP/GLP-1 receptor agonist for diabetes and obesity.
Oral GLP-1 drugs
Oral semaglutide and small-molecule GLP-1 agonists such as orforglipron.
Key point: In adults with obesity or overweight and type 2 diabetes, once-daily orforglipron reduced bodyweight versus placebo, with safety similar to other GLP-1 agonists.
Automated insulin delivery
Hybrid closed-loop systems that adjust insulin automatically.
Primary aldosteronism
Screening, diagnosis and treatment of primary aldosteronism.
Key point: Universal screening for primary aldosteronism in all patients with hypertension with an aldosterone-to-renin ratio test is now recommended.
Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
retatrutide[tiab] OR "triple agonist"[tiab] OR survodutide[tiab] OR cagrilintide[tiab] OR CagriSema[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.